Brain, Vol. 125, No. 7, 1450-1461,
July 2002
© 2002 Guarantors of Brain
A role for humoral mechanisms in the pathogenesis of Devic’s neuromyelitis optica
Departments of 1 Neurology, 2 Immunology and 3 Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, 4 Department of Neurology, George Washington University, Washington, DC, 5 Department of Neurosciences of The Lerner Research Institute and Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, Cleveland, OH, 6 Department of Neurology, Mayo Clinic, Scottsdale, AZ, USA, 7 Brain Research Institute, Vienna, Austria and 8 Department of Neuropathology, Charite, Berlin, Germany
Correspondence to: Claudia F. Lucchinetti, Associate Professor of Neurology, Mayo Clinic, Rochester, MN, USA E-mail: lucchinetti.claudia{at}mayo.edu
Devic’s disease [neuromyelitis optica (NMO)] is an idiopathic inflammatory demyelinating disease of the CNS, characterized by attacks of optic neuritis and myelitis. The mechanisms that result in selective localization of inflammatory demyelinating lesions to the optic nerves and spinal cord are unknown. Serological and clinical evidence of B cell autoimmunity has been observed in a high proportion of patients with NMO. The purpose of this study was to investigate the importance of humoral mechanisms, including complement activation, in producing the necrotizing demyelination seen in the spinal cord and optic nerves. Eighty-two lesions were examined from nine autopsy cases of clinically confirmed Devic’s disease. Demyelinating activity in the lesions was immunocytochemically classified as early active (21 lesions), late active (18 lesions), inactive (35 lesions) or remyelinating (eight lesions) by examining the antigenic profile of myelin degradation products within macrophages. The pathology of the lesions was analysed using a broad spectrum of immunological and neurobiological markers, and lesions were defined on the basis of myelin protein loss, the geography and extension of plaques, the patterns of oligodendrocyte destruction and the immunopathological evidence of complement activation. The pathology was identical in all nine patients. Extensive demyelination was present across multiple spinal cord levels, associated with cavitation, necrosis and acute axonal pathology (spheroids), in both grey and white matter. There was a pronounced loss of oligodendrocytes within the lesions. The inflammatory infiltrates in active lesions were characterized by extensive macrophage infiltration associated with large numbers of perivascular granulocytes and eosinophils and rare CD3+ and CD8+ T cells. There was a pronounced perivascular deposition of immunoglobulins (mainly IgM) and complement C9neo antigen in active lesions associated with prominent vascular fibrosis and hyalinization in both active and inactive lesions. The extent of complement activation, eosinophilic infiltration and vascular fibrosis observed in the Devic NMO cases is more prominent compared with that in prototypic multiple sclerosis, and supports a role for humoral immunity in the pathogenesis of NMO. Based on this study, future therapeutic strategies designed to limit the deleterious effects of complement activation, eosinophil degranulation and neutrophil/macrophage/microglial activation are worthy of further investigation.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  T. Vincent, P. Saikali, R. Cayrol, A. D. Roth, A. Bar-Or, A. Prat, and J. P. Antel Functional Consequences of Neuromyelitis Optica-IgG Astrocyte Interactions on Blood-Brain Barrier Permeability and Granulocyte Recruitment J. Immunol., October 15, 2008; 181(8): 5730 - 5737. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Hinson, S. F. Roemer, C. F. Lucchinetti, J. P. Fryer, T. J. Kryzer, J. L. Chamberlain, C. L. Howe, S. J. Pittock, and V. A. Lennon Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2 J. Exp. Med., October 6, 2008; (2008) jem.20081241. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Novak, A. E. Lovett-Racke, and M. K. Racke Monoclonal Antibody Therapies and Neurologic Disorders Arch Neurol, September 1, 2008; 65(9): 1162 - 1165. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Waters, S. Jarius, E. Littleton, M. I. Leite, S. Jacob, B. Gray, R. Geraldes, T. Vale, A. Jacob, J. Palace, et al. Aquaporin-4 Antibodies in Neuromyelitis Optica and Longitudinally Extensive Transverse Myelitis Arch Neurol, July 1, 2008; 65(7): 913 - 919. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. de Seze, F. Blanc, L. Jeanjean, H. Zephir, P. Labauge, M. Bouyon, L. Ballonzoli, G. Castelnovo, M. Fleury, S. Defoort, et al. Optical Coherence Tomography in Neuromyelitis Optica Arch Neurol, July 1, 2008; 65(7): 920 - 923. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E Moreh, I Gartsman, D Karussis, D Rund, N Hiller, and Z Meiner Seronegative neuromyelitis optica: improvement following lymphocytapheresis treatment Multiple Sclerosis, July 1, 2008; 14(6): 860 - 861. [PDF]
|
|
|
|
 |
|
 M. Krumbholz, H. Faber, F. Steinmeyer, L.-A. Hoffmann, T. Kumpfel, H. Pellkofer, T. Derfuss, C. Ionescu, M. Starck, C. Hafner, et al. Interferon-{beta} increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity Brain, June 1, 2008; 131(6): 1455 - 1463. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Marignier, J. De Seze, S. Vukusic, F. Durand-Dubief, H. Zephir, P. Vermersch, P. Cabre, G. Cavillon, J. Honnorat, and C. Confavreux NMO-IgG and Devic's neuromyelitis optica: a French experience Multiple Sclerosis, May 1, 2008; 14(4): 440 - 445. [Abstract] [PDF]
|
|
|
|
|
|
T. Carlson, M. Kroenke, P. Rao, T. E. Lane, and B. Segal The Th17-ELR+ CXC chemokine pathway is essential for the development of central nervous system autoimmune disease J. Exp. Med., April 14, 2008; 205(4): 811 - 823. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Matsushita, T. Matsuoka, T. Ishizu, H. Kikuchi, M. Osoegawa, Y. Kawano, F. Mihara, Y. Ohyagi, and J.-i. Kira Anterior periventricular linear lesions in optic-spinal multiple sclerosis: a combined neuroimaging and neuropathological study Multiple Sclerosis, April 1, 2008; 14(3): 343 - 353. [Abstract] [PDF]
|
|
|
|
 |
|
 M. J. Dinkin, D. M. Cestari, M. C. Stein, S. D. Brass, and S. Lessell NMO Antibody-Positive Recurrent Optic Neuritis Without Clear Evidence of Transverse Myelitis Arch Ophthalmol, April 1, 2008; 126(4): 566 - 570. [Full Text] [PDF]
|
|
|
|
|
|
R. A Wilcox, J. Burrow, M. Slee, J. Craig, and D. Thyagarajan Neuromyelitis optica (Devic's disease) in a patient with syphilis Multiple Sclerosis, March 1, 2008; 14(2): 268 - 271. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Levy, J. Birnbaum, and D. Kerr Finding NMO: Neuromyelitis optica in children Neurology, January 29, 2008; 70(5): 334 - 335. [Full Text] [PDF]
|
|
|
|
|
|
B. Banwell, S. Tenembaum, V. A. Lennon, E. Ursell, J. Kennedy, A. Bar-Or, B. G. Weinshenker, C. F. Lucchinetti, and S. J. Pittock Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders Neurology, January 29, 2008; 70(5): 344 - 352. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Pittock, V. A. Lennon, J. de Seze, P. Vermersch, H. A. Homburger, D. M. Wingerchuk, C. F. Lucchinetti, H. Zephir, K. Moder, and B. G. Weinshenker Neuromyelitis Optica and Non Organ-Specific Autoimmunity Arch Neurol, January 1, 2008; 65(1): 78 - 83. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Blanc, H. Zephir, C. Lebrun, P. Labauge, G. Castelnovo, M. Fleury, F. Sellal, C. Tranchant, K. Dujardin, P. Vermersch, et al. Cognitive Functions in Neuromyelitis Optica Arch Neurol, January 1, 2008; 65(1): 84 - 88. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Papais-Alvarenga, S. C. Carellos, M. P. Alvarenga, C. Holander, R. P. Bichara, and L. C. S. Thuler Clinical Course of Optic Neuritis in Patients With Relapsing Neuromyelitis Optica Arch Ophthalmol, January 1, 2008; 126(1): 12 - 16. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Hinson, S. J. Pittock, C. F. Lucchinetti, S. F. Roemer, J. P. Fryer, T. J. Kryzer, and V. A. Lennon Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica Neurology, December 11, 2007; 69(24): 2221 - 2231. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Marik, P. A. Felts, J. Bauer, H. Lassmann, and K. J. Smith Lesion genesis in a subset of patients with multiple sclerosis: a role for innate immunity? Brain, November 1, 2007; 130(11): 2800 - 2815. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Yuksel, N. Senbil, D. Yilmaz, and Y.K. Yavuz Gurer Devic's Neuromyelitis Optica in an Infant Case J Child Neurol, September 1, 2007; 22(9): 1143 - 1146. [Abstract] [PDF]
|
|
|
|
|
|
T. Braley and D. D. Mikol Neuromyelitis Optica in a Mother and Daughter Arch Neurol, August 1, 2007; 64(8): 1189 - 1192. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. S. Yu, C. Z. Zhu, K. C. Li, Y. Xuan, W. Qin, H. Sun, and P. Chan Relapsing Neuromyelitis Optica and Relapsing-Remitting Multiple Sclerosis: Differentiation at Diffusion-Tensor MR Imaging of Corpus Callosum Radiology, July 1, 2007; 244(1): 249 - 256. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. G. Weinshenker Neuromyelitis Optica Is Distinct From Multiple Sclerosis Arch Neurol, June 1, 2007; 64(6): 899 - 901. [Full Text] [PDF]
|
|
|
|
|
|
S. L. Galetta and J. Bennett Neuromyelitis Optica Is a Variant of Multiple Sclerosis Arch Neurol, June 1, 2007; 64(6): 901 - 903. [Full Text] [PDF]
|
|
|
|
|
|
G.J.D. Hengstman, P. Wesseling, C.W.G.M. Frenken, and P.J.H. Jongen Neuromyelitis optica with clinical and histopathological involvement of the brain Multiple Sclerosis, June 1, 2007; 13(5): 679 - 682. [Abstract] [PDF]
|
|
|
|
|
|
A. Compston Complexity and heterogeneity in demyelinating disease Brain, May 1, 2007; 130(5): 1178 - 1180. [Full Text] [PDF]
|
|
|
|
|
|
S. F. Roemer, J. E. Parisi, V. A. Lennon, E. E. Benarroch, H. Lassmann, W. Bruck, R. N. Mandler, B. G. Weinshenker, S. J. Pittock, D. M. Wingerchuk, et al. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis Brain, May 1, 2007; 130(5): 1194 - 1205. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Misu, K. Fujihara, A. Kakita, H. Konno, M. Nakamura, S. Watanabe, T. Takahashi, I. Nakashima, H. Takahashi, and Y. Itoyama Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis Brain, May 1, 2007; 130(5): 1224 - 1234. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Matsuoka, T. Matsushita, Y. Kawano, M. Osoegawa, H. Ochi, T. Ishizu, M. Minohara, H. Kikuchi, F. Mihara, Y. Ohyagi, et al. Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese Brain, May 1, 2007; 130(5): 1206 - 1223. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Takahashi, K. Fujihara, I. Nakashima, T. Misu, I. Miyazawa, M. Nakamura, S. Watanabe, Y. Shiga, C. Kanaoka, J. Fujimori, et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre Brain, May 1, 2007; 130(5): 1235 - 1243. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Ness, D. Chabas, A. D. Sadovnick, D. Pohl, B. Banwell, B. Weinstock-Guttman, and for the International Pediatric MS Study Group Clinical features of children and adolescents with multiple sclerosis Neurology, April 17, 2007; 68(16_suppl_2): S37 - S45. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Miyazawa, I. Nakashima, A. Petzold, K. Fujihara, S. Sato, and Y. Itoyama High CSF neurofilament heavy chain levels in neuromyelitis optica Neurology, March 13, 2007; 68(11): 865 - 867. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C Papeix, J-S Vidal, J de Seze, C Pierrot-Deseilligny, A Tourbah, B Stankoff, C Lebrun, T Moreau, P Vermersch, B Fontaine, et al. Immunosuppressive therapy is more effective than interferon in neuromyelitis optica Multiple Sclerosis, March 1, 2007; 13(2): 256 - 259. [Abstract] [PDF]
|
|
|
|
|
|
S Watanabe, I Nakashima, T Misu, I Miyazawa, Y Shiga, K Fujihara, and Y Itoyama Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica Multiple Sclerosis, January 1, 2007; 13(1): 128 - 132. [Abstract] [PDF]
|
|
|
|
 |
|
 S Love Demyelinating diseases. J. Clin. Pathol., November 1, 2006; 59(11): 1151 - 1159. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. F. Scott, S. L. Kassab, and S. J. Pittock Neuromyelitis optica IgG status in acute partial transverse myelitis. Arch Neurol, October 1, 2006; 63(10): 1398 - 1400. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I Nakashima, K Fujihara, I Miyazawa, T Misu, K Narikawa, M Nakamura, S Watanabe, T Takahashi, S Nishiyama, Y Shiga, et al. Clinical and MRI features of Japanese patients with multiple sclerosis positive for NMO-IgG J. Neurol. Neurosurg. Psychiatry, September 1, 2006; 77(9): 1073 - 1075. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G Giovannoni Neuromyelitis optica and anti-aquaporin-4 antibodies: widening the clinical phenotype J. Neurol. Neurosurg. Psychiatry, September 1, 2006; 77(9): 1001 - 1002. [Full Text] [PDF]
|
|
|
|
|
|
D Merkler, B Schmelting, B Czeh, E Fuchs, C Stadelmann, and W Bruck Myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis in the common marmoset reflects the immunopathology of pattern II multiple sclerosis lesions Multiple Sclerosis, August 1, 2006; 12(4): 369 - 374. [Abstract] [PDF]
|
|
|
|
|
|
R. Gold, C. Linington, and H. Lassmann Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research Brain, August 1, 2006; 129(8): 1953 - 1971. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. H. Lalive, T. Menge, I. Barman, B. A. Cree, and C. P. Genain Identification of new serum autoantibodies in neuromyelitis optica using protein microarrays. Neurology, July 11, 2006; 67(1): 176 - 177. [Full Text] [PDF]
|
|
|
|
|
|
B. Weinstock-Guttman, M. Ramanathan, N. Lincoff, S. Q. Napoli, J. Sharma, J. Feichter, and R. Bakshi Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (devic disease). Arch Neurol, July 1, 2006; 63(7): 957 - 963. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Pittock, B. G. Weinshenker, C. F. Lucchinetti, D. M. Wingerchuk, J. R. Corboy, and V. A. Lennon Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol, July 1, 2006; 63(7): 964 - 968. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Kister, S. Gulati, C. Boz, R. Bergamaschi, G. Piccolo, J. Oger, and M. L. Swerdlow Neuromyelitis optica in patients with myasthenia gravis who underwent thymectomy. Arch Neurol, June 1, 2006; 63(6): 851 - 856. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Jacob and M. Boggild Neuromyelitis optica Practical Neurology, June 1, 2006; 6(3): 180 - 184. [Full Text] [PDF]
|
|
|
|
|
|
D. M. Wingerchuk, V. A. Lennon, S. J. Pittock, C. F. Lucchinetti, and B. G. Weinshenker Revised diagnostic criteria for neuromyelitis optica Neurology, May 23, 2006; 66(10): 1485 - 1489. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Rubiera, J. Rio, M. Tintore, C. Nos, A. Rovira, N. Tellez, and X. Montalban Neuromyelitis optica diagnosis in clinically isolated syndromes suggestive of multiple sclerosis Neurology, May 23, 2006; 66(10): 1568 - 1570. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.S. Yu, F.C. Lin, K.C. Li, T.Z. Jiang, C.Z. Zhu, W. Qin, H. Sun, and P. Chan Diffusion tensor imaging in the assessment of normal-appearing brain tissue damage in relapsing neuromyelitis optica. AJNR Am. J. Neuroradiol., May 1, 2006; 27(5): 1009 - 1015. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M H Barnett, A P. Henderson, and J W Prineas The macrophage in MS: just a scavenger after all? Pathology and pathogenesis of the acute MS lesion Multiple Sclerosis, April 1, 2006; 12(2): 121 - 132. [Abstract] [PDF]
|
|
|
|
|
|
S. J. Pittock, V. A. Lennon, K. Krecke, D. M. Wingerchuk, C. F. Lucchinetti, and B. G. Weinshenker Brain abnormalities in neuromyelitis optica. Arch Neurol, March 1, 2006; 63(3): 390 - 396. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Nakamura, M Endo, K Murakami, H Konno, K Fujihara, and Y Itoyama An autopsied case of neuromyelitis optica with a large cavitary cerebral lesion Multiple Sclerosis, December 1, 2005; 11(6): 735 - 738. [Abstract] [PDF]
|
|
|
|
|
|
A. Y Poppe, Y. Lapierre, D. Melancon, D. Lowden, L. Wardell, L. M Fullerton, and A. Bar-Or Neuromyelitis optica with hypothalamic involvement Multiple Sclerosis, October 1, 2005; 11(5): 617 - 621. [Abstract] [PDF]
|
|
|
|
|
|
E. M. Frohman, O. Stuve, E. Havrdova, J. Corboy, A. Achiron, R. Zivadinov, P. S. Sorensen, J. T. Phillips, B. Weinshenker, K. Hawker, et al. Therapeutic Considerations for Disease Progression in Multiple Sclerosis: Evidence, Experience, and Future Expectations Arch Neurol, October 1, 2005; 62(10): 1519 - 1530. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. A. Lennon, T. J. Kryzer, S. J. Pittock, A.S. Verkman, and S. R. Hinson IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel J. Exp. Med., August 15, 2005; 202(4): 473 - 477. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Lolli, B. Mulinacci, A. Carotenuto, B. Bonetti, G. Sabatino, B. Mazzanti, A. M. D'Ursi, E. Novellino, M. Pazzagli, L. Lovato, et al. An N-glucosylated peptide detecting disease-specific autoantibodies, biomarkers of multiple sclerosis PNAS, July 19, 2005; 102(29): 10273 - 10278. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Ishizu, M. Osoegawa, F.-J. Mei, H. Kikuchi, M. Tanaka, Y. Takakura, M. Minohara, H. Murai, F. Mihara, T. Taniwaki, et al. Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis Brain, May 1, 2005; 128(5): 988 - 1002. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. A.C. Cree, S. Lamb, K. Morgan, A. Chen, E. Waubant, and C. Genain An open label study of the effects of rituximab in neuromyelitis optica Neurology, April 12, 2005; 64(7): 1270 - 1272. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Correale and M. Fiol Activation of humoral immunity and eosinophils in neuromyelitis optica Neurology, December 28, 2004; 63(12): 2363 - 2370. |